http://www.youtube.com/watch?v=5qAbj4Nh_eo
Thanks for checking - Feel free to contact me regarding trading services, education and access to my daily guest appearance broadcast.
Tim@affinitytrading.com
Wednesday, March 13, 2013
Friday, March 8, 2013
Affymax seeing volatility this morning, currently going back positive
$AFFY Affymax seeing volatility this morning,
Shares of Affymax have seen heightened volatility this morning on heavy
volume. There was a rumor earlier that a representative from Fresenius (a
dialysis company that is a large potential client) made positive comments about
Affymax's OMONTYS, however, these rumors have been proven false. A Reuters
reporter said that Takeda said it is committed to working with Affymax to
understand the root cause of the OMONTYS recall but this is no surprise given
that Takeda is Affymax's partner for the drug. Yesterday's sharp move higher is
still difficult to explain given that no new material information has come to
light. Affymax is scheduled to report earnings in mid-March so it is possible
that the company could provide an update regarding the investigation of the
three patients who died after receiving OMONTYS in February.
Thanks for checking - Feel free to contact me regarding trading services, education and access to my daily guest appearance broadcast. Tim@affinitytrading.com ***DISCLOSURE: This material is being provided to you for educational purposes only. No information presented constitutes a recommendation by Legend Trading or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy. The content neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy, sell, or hold any securities. You are fully responsible for any investment decisions you make. Such decisions should be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance and liquidity needs.
Shares of Affymax have seen heightened volatility this morning on heavy
volume. There was a rumor earlier that a representative from Fresenius (a
dialysis company that is a large potential client) made positive comments about
Affymax's OMONTYS, however, these rumors have been proven false. A Reuters
reporter said that Takeda said it is committed to working with Affymax to
understand the root cause of the OMONTYS recall but this is no surprise given
that Takeda is Affymax's partner for the drug. Yesterday's sharp move higher is
still difficult to explain given that no new material information has come to
light. Affymax is scheduled to report earnings in mid-March so it is possible
that the company could provide an update regarding the investigation of the
three patients who died after receiving OMONTYS in February.
Thanks for checking - Feel free to contact me regarding trading services, education and access to my daily guest appearance broadcast. Tim@affinitytrading.com ***DISCLOSURE: This material is being provided to you for educational purposes only. No information presented constitutes a recommendation by Legend Trading or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy. The content neither is, nor should be construed as, an offer, or a solicitation of an offer, to buy, sell, or hold any securities. You are fully responsible for any investment decisions you make. Such decisions should be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance and liquidity needs.
Sunday, March 3, 2013
Proprietary Trading Opportunity
Quasar Trading, LLC, NASDAQ, OMX & PHLX member firm is now expanding its Financial District office. Our firm is currently seeking individuals for membership consideration. This opportunity provides qualified candidates with an opportunity to trade the NYSE, AMEX, and NASDAQ equity markets. Quasar Trading provides the opportunity to jump start your career on Wall Street.
If you're an experienced trader and would like to operate from a home-office environment, we also offer remote trading. If you're already trading retail, professionally or are a new candidate, check out this opportunity to be considered as a registered professional proprietary equities trader. Complimentary one on one trading model evaluations available on request.
Quasar Trading’s business model is based on close relationships with our registrants. We're currently searching for qualified individuals that are disciplined, motivated, passionate, and possessing the ability to adapt in a high-paced environment.
Our New York City office provides:
- Access to consistently profitable seasoned veterans
- Professional direct access trading platforms
- Access to firm capital
- Comprehensive risk management tools
- Technical and administrative support staff on site
- Professional trading desk
- Competitive routing to ECN's and dark pools
- Synergistic trading floor environment
- Experienced management with a focus on compliance and transparency
- Daily trading performance prop reports
- Weekly seminars - one on one training
- Algorithmic quant programming support
- Trading Platform access from 4 AM to 8 PM est
- General Securities License Series 7 & 57 sponsorship and support
- Daily full time mentoring from experienced traders
- Daily AM/PM meetings, game-plans, market recap analysis.
- Indiviual trading reviews performed regularly
- Simulation mode trading exercises
- Risk management analysis, trading review's, and progress evaluation
- Strong interest in trading U.S. equities & options
- Proactively risk adverse personality
- Competitive drive
- Entrepreneurial
- Persistent
- Resilient
- U.S. Citizen or valid visa
Tim Kelleher
Business Development Executive
Quasar Trading, LLC
tim.kelleher@quasar-trading.com
http://quasartrading.com/
Subscribe to:
Posts (Atom)